Plasma Protein Therapeutics Market Size & Share, By Product (Human Serum Protein, Plasma-Derived Clotting Factor), Application (Research Laboratories And Institutions, Hospitals), Regional Forecast, Industry Players, Growth Statistics Report 2024-2035

Market Outlook:

Plasma Protein Therapeutics Market size exceeded USD 30.85 Billion in 2023 and is estimated to cross USD 67.28 Billion by 2035, growing at over 9.51% CAGR during 2024 to 2035.

• Base Year Value (2023): USD 30.85 Billion
• CAGR (2024-2035): 9.51%
• Forecast Year Value (2035): USD 67.28 Billion
• Historical Data Period: 2019-2022
• Largest Region: North America
• Forecast Period: 2024-2035

Market Dynamics:

The global plasma protein therapeutics market is expected to grow at a rapid pace in the coming years, driven by various factors such as increasing prevalence of rare and chronic diseases, rising geriatric population, and growing awareness about plasma protein therapies. Additionally, advancements in the healthcare infrastructure and increasing investment in research and development activities are also contributing to the market growth.

Growth Drivers & Opportunity:

One of the key growth drivers for the plasma protein therapeutics market is the increasing prevalence of rare and chronic diseases such as hemophilia, immune deficiencies, alpha-1 antitrypsin deficiency, and hereditary angioedema. According to the World Federation of Hemophilia, an estimated 400,000 individuals worldwide have hemophilia, and approximately 75% of them are undiagnosed or untreated. This presents a significant opportunity for plasma protein therapeutics manufacturers to cater to the unmet medical needs of these patients and drive market growth.

Furthermore, the rising geriatric population is also expected to drive the demand for plasma protein therapies, as older individuals are more prone to various chronic and immune-related disorders. According to the World Health Organization, the global geriatric population is expected to reach 2 billion by 2050, which will significantly increase the demand for plasma protein therapeutics.

Report Scope

Report Coverage	Details
Segments Covered	By Product, Application
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Baxter, CSL Behring, Grifols Therapeutics, Octapharma, Abeona Therapeutics, ADMA Biologics, Amag Pharmaceuticals, Antares Pharma, BioDelivery Sciences, Bio Products Laboratory, Biota Pharmaceuticals, Biotest Pharmaceuticals, and China Biologic Products.

Industry Restraints & Challenges:

Despite the promising growth prospects, the plasma protein therapeutics market is not without its challenges. One of the major restraints for market growth is the high cost associated with plasma protein therapies. These therapies often require long-term treatment, leading to a substantial financial burden on patients and healthcare systems. Additionally, stringent regulatory requirements and quality standards for plasma protein products also pose a challenge for market players, leading to a slow approval process and limited product availability.

Moreover, the risk of viral contamination in plasma-derived products continues to be a concern for patients and healthcare providers. Although advancements in manufacturing processes and stringent regulatory oversight have reduced the risk of viral transmission, the potential for contamination remains a challenge for the plasma protein therapeutics market.

Regional Forecast:

North America:

North America is expected to dominate the plasma protein therapeutics market, owing to the presence of well-established healthcare infrastructure, increasing R&D activities, and high prevalence of rare diseases. Additionally, favorable reimbursement policies and rising awareness about plasma protein therapies are further driving market growth in the region. According to the Plasma Protein Therapeutics Association, the United States is the largest exporter of plasma-derived medicinal products, accounting for approximately 70% of the global share.

Asia Pacific:

The Asia Pacific region is expected to witness significant growth in the plasma protein therapeutics market, driven by increasing healthcare expenditure, growing geriatric population, and rising prevalence of rare diseases. Moreover, the presence of a large patient pool, particularly in countries like India and China, presents a lucrative opportunity for market players to expand their presence in the region. However, challenges such as stringent regulatory requirements and limited access to plasma protein therapies in rural areas could hinder market growth in some parts of Asia Pacific.

Europe:

Europe is anticipated to be a key market for plasma protein therapeutics, supported by the presence of advanced healthcare infrastructure, high healthcare expenditure, and favorable reimbursement policies. The region is also home to several prominent market players and research institutions, fostering the development of innovative plasma protein therapies. However, the market growth in Europe may be hindered by the impact of Brexit, changes in regulatory frameworks, and price pressures on plasma protein products.

In conclusion, the global plasma protein therapeutics market is poised for significant growth in the coming years, driven by factors such as increasing prevalence of rare diseases, rising geriatric population, and growing demand for innovative therapies. Despite the challenges and restraints, market players are expected to capitalize on the lucrative opportunities presented by the market dynamics and regional forecasts.

Segmentation Analysis:

1. Product Type: Immunoglobulins

Immunoglobulins, also known as antibodies, are proteins produced by plasma cells in response to antigens such as bacteria, viruses, and foreign substances in the body. These proteins play a crucial role in the immune system and are used for the treatment of primary and secondary immunodeficiency disorders. Immunoglobulins are further classified into intravenous and subcutaneous immunoglobulins. Intravenous immunoglobulins are administered directly into the bloodstream, while subcutaneous immunoglobulins are injected under the skin. The increasing prevalence of immunodeficiency disorders and the rising demand for immunoglobulin therapy are driving the growth of this sub-segment in the plasma protein therapeutics market.

2. Application: Hemophilia

Hemophilia is a genetic bleeding disorder characterized by the deficiency of clotting factors in the blood. Plasma protein therapeutics such as clotting factor concentrates are used for the treatment of hemophilia to replace the missing or deficient clotting factors. These products are available for both hemophilia A (deficiency of factor VIII) and hemophilia B (deficiency of factor IX). The development of extended half-life clotting factor concentrates and the introduction of gene therapy for hemophilia are expected to drive the growth of this sub-segment in the plasma protein therapeutics market.

Competitive Landscape:

The global plasma protein therapeutics market is highly competitive with the presence of several established players as well as new entrants. Some of the key players in the market include Grifols, S.A., CSL Behring, Shire (Baxalta), Octapharma AG, Kedrion Biopharma, and Takeda Pharmaceutical Company Limited. These companies are focused on expanding their product portfolio, investing in research and development, and strategic collaborations to gain a competitive edge in the market. Additionally, the market players are also focusing on geographic expansion in emerging economies to capitalize on the growing demand for plasma protein therapeutics.

In conclusion, the plasma protein therapeutics market is witnessing significant growth due to the rising prevalence of rare and chronic diseases, increasing geriatric population, and advancements in medical technology. The market is segmented based on product type and application, with immunoglobulins and hemophilia being key sub-segments driving market growth. The competitive landscape of the market is characterized by intense competition among key players who are striving to expand their product offerings and geographic presence to gain a competitive advantage.